PDE4 inhibitors: current status

REVIEW PDE4 inhibitors: current status

Phosphodiesterase4 inhibitors are currently under development for the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease. The rationale for the development of this drug class stems from our understanding of the role of PDE4 in suppressing the function of a range of inflammatory and resident cells thought to contribute toward the pathogenesis of these di...

Current Development Status of MEK Inhibitors.

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of t...

Aurora Kinase Inhibitors: Current Status and Outlook

The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases important for mitosis. Their activity and protein expression are cell cycle regulated, peaking during mitosis to orchestrate important mitotic processes including centrosome maturation, chromosome alignment, chromosome segregation, and cytokinesis. In humans, the Aurora kinase family consists of three members; A...

Current status of aldose reductase inhibitors.

Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far.

The beginning of the 1990s saw the synthesis and evaluation of orally-active, second generation phosphodiesterase (PDE) inhibitors that have high specificity for the PDE4 subtype. In vitro and in vivo studies established that this class of compounds suppresses the activity of many pro-inflammatory and immune cells indicating that they may be effective in the treatment of airway inflammatory dis...